FDA OKs Linerixibat for Cholestatic Pruritus



The oral ileal bile acid transporter inhibitor significantly and rapidly reduced cholestatic pruritus in patients with PBC in the phase 3 GLISTEN trial.
Medscape Medical News



Source link : https://www.medscape.com/viewarticle/linerixibat-lynavoy-cholestatic-pruritus-wins-fda-nod-2026a10008h1?src=rss

Author :

Publish date : 2026-03-19 19:14:00

Copyright for syndicated content belongs to the linked Source.
Exit mobile version